Previous 10 | Next 10 |
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiova...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardi...
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment communi...
- 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevluma...
Shares of FibroGen Inc (NASDAQ:FGEN) traded today at $68.20, eclipsing its 52-week high. So far today approximately 47.6 million shares have been exchanged, as compared to an average 30-day volume of 790,000 shares. In the past 52 weeks, FibroGen Inc share prices are bracketed by a curre...
Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia. With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for a...
The following slide deck was published by FibroGen, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: FibroGen, Inc. 2021 Q4 - Results - Earnings Call Presentation
FibroGen, Inc. (FGEN) Q4 2021 Earnings Conference Call February 28, 2022, 05:00 PM ET Company Participants Michael Tung - VP, Corporate Strategy and IR Enrique Conterno - CEO Juan Graham - CFO Mark Eisner - CMO John Hunter - CSO Thane Wettig - CCO Chris Chung - SVP, China Operations Conferenc...
FibroGen press release (NASDAQ:FGEN): Q4 GAAP EPS of -$1.45 misses by $0.74. Revenue of $16.54M (-74.5% Y/Y) misses by $31.11M. For further details see: FibroGen GAAP EPS of -$1.45 misses by $0.74, revenue of $16.54M misses by $31.11M
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy Total company revenue increased from $176.3 million in 2...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2024 financial results on Monday, May...
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further det...
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that clinical data from the dose escalation porti...